Evidence mapPaperPMID 38524871Full record

ReviewInternational journal of endocrinology2024

Coenzyme Q10: A Key Antioxidant in the Management of Diabetes-Induced Cardiovascular Complications-An Overview of Mechanisms and Clinical Evidence.

Fatemeh Samimi, Nasim Namiranian, Ali Sharifi-Rigi, Morvarid Siri, Omid Abazari, Sanaz Dastghaib

Open access · goldAbstract readReview
In one paragraph

Review in International journal of endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Optimized CoQ10 deliveryRSC advances · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Coenzyme QMetabolic brain disease · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Ferroptosis as an emerging target in sickle cell disease.Current research in toxicology · 2024
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fatemeh SamimiDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID https://orcid.org/0000-0001-5426-6785
Nasim NamiranianDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID https://orcid.org/0000-0002-5133-6204
Ali Sharifi-RigiDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0009-0001-1313-2681
Morvarid SiriAutophagy Research Center, Department of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-5556-2102
Omid AbazariDepartment of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.ORCID https://orcid.org/0000-0002-6751-1564
Sanaz DastghaibEndocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0001-8553-9221
Shiraz University of Medical Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetes mellitus (DM) presents a significant global health challenge with considerable cardiovascular implications. Coenzyme Q10 (CoQ10) has gained recognition for its potential as a natural antioxidant supplement in the management of diabetes and its associated cardiovascular complications. Aim: This comprehensive review systematically examines the scientific rationale underlying the therapeutic properties of CoQ10 in mitigating the impact of diabetes and its cardiovascular consequences. The analysis encompasses preclinical trials ( Conclusion: In conclusion, CoQ10 emerges as a promising natural therapeutic intervention for the comprehensive management of diabetes and its associated cardiovascular complications. Its multifaceted impacts on the Nrf2/Keap1/ARE pathway, oxidative stress, and metabolic regulation highlight its potential as an adjunct in the treatment of diabetes and related cardiovascular disorders. However, further extensive clinical investigations are necessary to fully establish its therapeutic potential and assess potential synergistic effects with other compounds.

Identifiers

PMID38524871
PMCPMC10959587
OpenAlexW4394739321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.